Doctor Joaquim Bellmunt is the Director of the Bladder Cancer Center at the Dana-Farber Cancer Institute (DFCI) and the Dana-Farber/Brigham and Women’s Cancer Center, Harvard University, United States. He combines this work with the management of the Dr. Bellmunt Cancer Institute based at the University Hospital Quirón Dexeus in Barcelona. He is also the Associate Professor of Medicine at Harvard Medical School and Attending Physician of Solid Tumor Oncology at DFCI.

Associate Professor JOAQUIM BELLMUNT MD, PhD Dana Farber Cancer Center Director of the Bladder Cancer Centre Associate Professor of Medicine Harvard Medical School Boston, USA

Dr. Bellmunt graduated in Medicine and Surgery in 1982 and received his PhD in 1989, both from the Autonomous University of Barcelona, Spain. He completed his Medical Oncology Residency at the University Hospital Vall d’Hebron, in Barcelona, Spain. He gained his European Certificate of Medical Oncology in London and New York. He has worked as Chief of the Solid Tumor Oncology Service of the Hospital del Mar, Spain. In 2008 Dr. Bellmunt was appointed as a Visiting Associate Professor at Harvard University. He has also worked as Associate Professor of Medicine at Pompeu Fabra University, Spain, and has directed the Dr. Bellmunt Oncological Institute at Clinica Quiron-Dexeus in Barcelona. His research interests lie in clinical genitourinary oncology, and translational and early clinical research in the area of immunotherapy, growth factor receptors and downstream molecules as targets for cancer therapy. Dr. Bellmunt is a member of the American Association for Cancer Research, American Society of Clinical Oncology, the European Society for Medical Oncology (ESMO), and the Spanish Society of Medical Oncology. He has also been part of the American Congress Scientific Committee of the American Society of Clinical Oncology Genitourinary. He is Past-President and Co-founder of the Spanish Oncology Genitourinary Group (SOGUG), a Consultant for the EORTC GU Group, and Chairman of the group’s Advanced Bladder Committee. Dr. Bellmunt is an adhoc reviewer of several Journals including the Journal of Clinical Oncology, Lancet Oncology, Annals of Oncology, European Urology, European Journal of Cancer, the British Journal of Urology International, and the Journal of Urology, among others. Recent publications include: • Guancial EA, Werner L, Bellmunt J et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014 May 21. doi: 10.1002/cam4.262. • Choueiri TK, Jacobus S, Bellmunt J et al. Neoadjuvant dosedense methotrexate, vinblastine, Doxorubicin, and Cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 20; 32: 1889-1894. • Bellmunt J, Pons F, Foreshew A et al Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. Clin Genitourin Cancer. 2014 Mar 14. pii: S1558-7673(14)00051-2. doi: 10.1016/j.clgc.2014.03.002. [Epub ahead of print] • Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, Bellmunt J. Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. Eur Urol. 2014; 66: 42-54. • Bellmunt J, Teh BT, Tortora G, Rosenberg JE. Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol. 2013; 10: 557-570. Dr. Joaquim Bellmunt has declared lecture fees and advisory board for Pierre Fabre, Oncogenex and Novartis

Doctor FILIPPO DE BRAUD MD Director, Medical Oncology Division National Cancer Institute Milan, Italy

Doctor Filippo de Braud, MD, is currently Director of the Medical Oncology Department and Division of the National Cancer Institute in Milan, Italy, where his principal area of expertise is clinical research in oncology. In 1984, Dr. de Braud received his medical degree in medicine from the University of Milan. He continued his training in oncology at various institutions, including the Royal Free Hospital School of Medicine, London, UK, Wayne State University, Detroit, MI, USA, and the Institute Gustave Roussy in Paris, France. He has held clinical posts at the European Institute of Oncology, where he was appointed Deputy Director of the Medical Oncology Division in 1994, later becoming Director of Division of Clinical Pharmacology and New Drugs Development. In August 2011, he was appointed as Chief of Division of Medical Oncology at the National Cancer Institute, Milan. He is leading teams of researchers focusing on the development of new drugs (Phase I and early Phase II studies) and teaches at universities in Milan, Rome and Ferrara. Since 2000, he has been appointed Scientific Advisor and Committee Member at the Italian Medicine Agency AIFA, the Ministry of Health, and several pharmaceutical companies. Dr. de Braud is the author or co-author of over 200 publications in medical oncology. Recent publications include: • Panzuto, F., Rinzivillo, M., Fazio, N., De Braud, F., et al. 2014. Realworld study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. ;19(9):966-74. • Celio L, de Braud F, Aapro M. (2014) Aprepitant versus dexamethasone for delayed emesis: what is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron? J Clin Oncol.32(20):2185-6. • Buzzoni, R., Pusceddu, S., Bajetta, E., De Braud, F., et al. 2014. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Ann Oncol. ;25(8):1597-603. Dr. De Braud has declared advisory role for Novartis. role for Novartis. role for Novartis.

Doctor FATIMA CARDOSO MD ESO Breast Cancer Program Coordinator EORTC Secretary General Director, Breast Unit, Champalimaud Cancer Center Lisbon, Portugal

Doctor Cardoso is the Director of the Breast Unit of the Champalimaud Cancer Center in Lisbon, Portugal. Dr. Cardoso earned her medical degree at the University of Porto in Portugal and completed fellowships in the Translational Research Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium, and the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center in Houston, Texas. She then worked for 10 years as Assistant Professor at the Medical Oncology Clinic of the IJB where, besides her clinical work, she was active in the Translational Research Unit and was responsible for phase II-III trials in breast cancer. She is board certified in medical oncology and internal medicine. Dr. Cardoso’s research interests include biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents. She is actively involved in a number of phase I-III breast cancer clinical trials and served as the scientific director of the international research network TRANSBIG for 7 years. Dr. Cardoso is actively involved in numerous professional organizations such as ESMO, ECCO, EORTC, ASCO, and AACR where she serves on several committees, and is the current EORTC Secretary General and vice-chair of the EORTC-Breast Cancer Group. She is the Breast Cancer Program Coordinator of the European School of Oncology and co-chair of the Advanced Breast Cancer International Consensus Guidelines Conference (ABC). Dr. Cardoso is editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals. She has received several educational and research grants from the Breast Cancer Research Foundation, the European Society of Medical Oncology (ESMO), the European Cancer Organization (ECCO), the Portuguese Science and Technology Foundation (FCT), the Portuguese League Against Cancer, the Portuguese Ministry of Health, the Free University of Brussels, the “Fonds Jean-Claude Heuson”, the Fondation Lambeau-Marteau, the Belgian Federation Against Cancer, the Susan G. Komen Foundation, and the European Union Framework VI Programme. Dr. Cardoso has authored over 200 publications and has presented her work nationally and internationally. Dr. Cardoso has reported consultancy/honoraria and advisory boards for Eisai, Roche, GlaxoSmithKline, Novartis, Astra-Zeneca, Pfizer, Astellas, GE Oncology, Sanofi, Daiichi-Sankyo, Merus, Celgene, MSD, Genentech.

Doctor PAOLO G. CASALI MD Head of Adult Mesenchymal Tumor Medical Oncology Unit Istituto Nazionale dei Tumori Milan, Italy

Doctor Paolo G. Casali is Head of the Adult Sarcoma Medical Oncology Unit at the Istituto Nazionale Tumori in Milan, Italy, and serves as Secretary of the Ethics Committee at this institution. Dr. Casali received his medical degree in 1984 and he was certified in Hematology in 1987 at the University of Milan, Italy. He is also certified in Clinical Oncology from the University of Parma, Italy. He holds the ESMO Certificate in Medical Oncology. Dr. Casali’s clinical and research activities focus on rare tumours, especially adult sarcomas, including gastrointestinal stromal tumours and uncommon histotypes. An active member of ESMO, Dr. Casali serves on the executive board and chairs the Public Policy Committee. He is a member of the Guidelines Working Group. He is also a member of the Policy Committee of the European Cancer Organisation (ECCO), and the European Organisation for Research and Treatment of Cancer (EORTC) – Soft Tissue & Bone Sarcoma Group. Dr. Casali chairs the Italian Network on Rare Tumors and is Secretary of the Italian Sarcoma Group, a national cooperative group for clinical and translational research on soft tissue and bone sarcomas. He is an editor of START (State-of-the-Art Oncology in Europe), an Italian-based, European state-of-the-art instrument on cancer treatment. Dr. Casali serves on the editorial board for Cancer Treatment Reviews, and is Editor-inChief of Clinical Sarcoma Research. Recent publications include: • Casali PG (2014) Successes and limitations of targeted cancer therapy in gastrointestinal stromal tumors. Prog Tumor Res.;41:51-61. • Radaelli S, Stacchiotti S, Casali PG, et al. (2014) Emerging therapies for adult soft tissue sarcoma. Expert Rev Anticancer Ther.;14(6):689-704. • Ciardiello F, Arnold D, Casali PG, et al. (2014) Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol.;25(9):1673-8. Dr. Casali has reported honoraria for consultancy/advisory role and/ or for lectures, and/or had travel coverage for medical meetings from: ARIAD, Bayer, Glaxo SK, Janssen Cilag, MSD, Novartis, Pfizer, PharmaMar, Sanofi and Infinity.

Doctor GEERT CIRKEL MD Medical Doctor University Medical Center Utrecht Utrecht, The Netherlands

Geert Cirkel received his medical degree from the University of Utrecht in 2006. Afterwards he entered the residency program of Internal Medicine at the University Medical Center, Utrecht. During his clinical training he entered a PhD project at the department of Medical Oncology at the University Medical Center Utrecht, under supervision of prof. Dr. E.E. Voest. On behalf of the Dutch Tumor Immunology Working Party for renal cell carcinoma, he successfully initiated a clinical multicenter trial focusing on an alternative treatment strategy in renal cell carcinoma. Additionally he is involved in the Center for Personalized Cancer Treatment (CPCT), a joint effort of some of the largest hospitals in the Netherlands. The aim of the CPCT is to describe the genetic features of each individual tumour, ultimately leading to a personalized treatment approach for each patient. He is expected to register as an clinical oncologist in 2018. Geert Cirkel has reported no potential conflicts of interest.

Doctor KATRIN LISA CONEN MD, PhD Medical Oncologist Department of Medical Oncology University Hospital in Basel, Switzerland

Doctor Katrin Lisa Conen is Medical Oncologist at the Department of Medical Oncology of the University Hospital in Basel, Switzerland. Dr. Conen graduated in Medicine in 2003 from the University of Würzburg, Germany and was awarded her PhD in 2005. She then completed a fellowship in Internal Medicine in Basel, Switzerland. From 2006 to 2008, she undertook a research fellowship focusing on bone biology in Massachusetts General Hospital, USA. She was registered as an Internist in 2010 and as a Medical Oncologist in 2013. She has specialist interests in brain tumour treatment and in supportive and palliative medicine. Dr. Conen has co-authored eight peer-reviewed articles and one book chapter. Recent publications include: • Conen, K.L., Jeanneret, C., Hecker, B., Cathomas, G., and Biedermann, B.C. (2006) Acute occlusive large vessel disease leading to fatal stroke in a patient with systemic lupus erythematosus: arteritis or atherosclerosis? Arthritis and Rheumatism. 54: 908–913. • Conen, K.L., Nishimori, S., Provot, S., et al. (2009) The transcriptional cofactor Lbh regulates angiogenesis and endochondral bone formation during fetal bone development. Developmental Biology. 333: 348–358. • Conen, K.L., Fischer, N., Hofbauer, G.F,. et al. (2014) Cetuximab in Metastatic Squamous Cell Cancer of the Skin: A Swiss case Series. Dermatology. 2014 Jun 7 [Epub ahead of print]. Dr. Conen has reported honoraria from MSD and Roche.

Doctor VITTORIA COLIA MD Adult Mesenchymal Tumor Medical Oncology Unit Fondaz IRCCS Istituto Nazionale Tumori Milan, Italy

Doctor Vittoria Colia is a Medical Oncology Fellow working in the Mesenchymal Tumor Medical Oncology Unit at University College Hospital of London. Dr. Colia is currently a Clinical Fellow at the University College Hospital of London training in Medical Oncology at the Mesenchymal Tumor Unit, where she has an Honorary Contract for one year; her clinical and research activities focus on adult soft tissue and bone sarcomas. In 2013 she was actively involved in sarcoma care at Istituto Nazionale Tumori, Milan. Dr. Colia received her medical degree in 2009 and then she had training periods in Medical Oncology at two general hospitals in Milan, where she followed non-sarcoma patients which allowed her to acquire good experience of general medical oncology. Before completing her studies, she worked as a Medical Student Volunteer at the Institute for Indian Mother and Child ONLUS, in Kolkata, India. Dr. Colia is a member of the European Society for Medical Oncology (ESMO). Dr. Colia has declared no potential conflicts of interest.

Doctor SIMONE FERRERO MD Research Fellow Division of Haematology Department of Molecular Biotechnologies and Health Sciences University of Torino, Italy

Doctor Simone Ferrero is a Research Fellow in the Department of Molecular Biotechnologies and Health Sciences within the Division of Haematology at the University of Torino, Italy. Dr. Ferrero completed a degree in Medicine and Surgery in 2007 and was awarded a post-graduate degree in Haematology in 2012 from the University of Torino, Italy. He also earned a German language degree in 2012 from Goethe Institut, Germany. He worked as a PostDoctoral Fellow in the Division of Haematology for the University of Torino. He also was a Research Fellow in the Department of Internal Medicine at the University Hospital Munich, Germany, in 2012 and 2013, and a Research Fellow in the Laboratory of Molecular Genetics at the University Hospital Kiel, Germany, in 2013. His main interests are lymphoproliferative diseases, minimal residual disease assessment in non-Hodgkin lymphoma and multiple myeloma, and the molecular pathogenesis of lymphoma and myeloma. Further interests include the genetics of immunoglobulin genes, and biological prognostic factors in non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Dr. Ferrero is a member of the Italian Lymphoma Foundation (FIL) and of the European Hematology Association. He is an expert referee for the Swiss Group for Clinical Cancer Research (SAKK), and a reviewer for the journal Clinical Lymphoma, Myeloma & Leukemia. Recent publications include: • Ferrero, S., Ladetto, M., Drandi, D., et al. (2014) Long-term results of the gimena vel-03-096 trial in mm patient receiving vtd consolidation after asct: mrd kinetics impact on survival. Leukemia 2014 Jul 16. doi 10.1038/leu.2014.219 [Epub ahead of print]. • Ladetto M., Brüggemann M., Monitillo L., Ferrero S., et al (2014) Next-generation sequencing and real-time quantitative PCR for minimal residual disease (MRD) detection using the immunoglobulin heavy chain variable region: a methodical comparison in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL) and multiple myeloma (MM). Leukemia 28:1299-07. • Ferrero, S., Monitillo, L., Mantoan, B., et al. (2013) Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. Annals of Hematology 2013 Nov;92(11):1503-11. doi: 10.1007/s00277-013-1797-y. • Ferrero, S., Drandi, D., Mantoan, B., et al. (2011) Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. Hematological Oncology 29: 167-76. • Ladetto, M., Pagliano, G., Ferrero, S., et al. (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thealidomide, and dexamethasone in patients with autografted myeloma. Journal of Clinical Oncology 28: 2077-84. Dr. Ferrero has reported speaker’s honoraria for Mundipharma.

Doctor CATERINA FONTANELLA MD Trainee Doctor Department of Medical Oncology University Hospital of Udine, Italy

Doctor Caterina Fontanella is a trainee doctor at the Department of Medical Oncology, University Hospital of Udine, Italy. She gained her Medical Degree in March 2010 from the University of Trieste, Italy. During her training program, she has gained experience in the management of in and out patients with a wide range of adult solid tumours, as well as the administration of anticancer agents and management of drug-related adverse events. From January 2013 to March 2014, she worked as a research fellow at the German Breast Group (Neu-Isenburg, Germany), where she increased her experience in the design and management of clinical trials, data management, data managing, investigational drug administration, and the publishing process. In November 2013 she was selected as the recipient of the Monica Boscolo Research Grant 2013 with a project focused on the predictive value of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene methylation in triple-negative breast cancer patients receiving alkylating agents. She was also selected to attend the FLIMS Workshop in Clinical Trials in June 2014. Dr. Caterina Fontanella is a member of the Italian Medical Oncology Association (AIOM), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). Recent publications include: • Fontanella C, Lederer B, Nekljudova V, Untch M, von MinckwitzG, Loibl S. Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib. Accepted for publication by Journal of Clinical Oncology in 2014. • von Minckwitz G, Fontanella C. Comprehensive review on the surrogate endpoints of efficacy proposed or hypothesized in the scientific community today. Accepted for publication by JNCI Monographs in 2014. • Puglisi F, Fontanella C, Numico G et al. Follow-up of patients with early breast cancer: is it time to rewrite the story? Crit Rev Oncol Hematol. 2014 Mar 22. pii:S1040-8428(14)00050-X. doi: 10.1016/j.critrevonc.2014.03.001. [Epub ahead of print] Dr. Fontanella has reported no potential conflicts of interest.

Doctor MARINA CHIARA GARASSINO MD Chief of Thoracic Oncology Unit Medical Oncology Division National Cancer Institute of Milan, Italy

Doctor Marina Garassino is the chief of the Thoracic Oncology unit of the National Cancer Institute of Milan, Italy. Dr. Garassino received her medical degree in 1995 and achieved her board specialisation in Oncology in 1999 from the University of Milan. She then continued her training in oncology at various European institutions. From 2005 to 2011, she held a clinical post at the Fatebenefratelli Ophthalmic Hospital in Milan; in 2001, she founded the AIOM Giovani (Italian Young Oncologists Committee). She specialises in thoracic oncology and was the coordinator of the TAILOR trial (NCT00637910). Dr. Garassino serves on several national and international committees and task forces. She is an active member of ESMO and a member of the ESMO Publishing Working Group; she has been serving as the ESMO National Representative in Italy since 2012. She is also a member of the ESMO Lung Cancer Faculty and the ESMO Public Policy Committee. In addition, she served on the local committee for the ESMO Congress 2010 in Milan. Recent publications include: • Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013; 14(10):981–8. • Garassino MC, Piva S, La Verde N, et al. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One. 2013;8(4):e59981. doi: 10.1371/journal.pone.0059981. Epub 2013 Apr 5. Dr. Marina Garassino has reported consultancy and/or honoraria fees from Eli Lilly, MSD, Medimmune, and Boehringer Ingelheim.

Doctor EVA REGINA HASPINGER MD Medical Doctor National Cancer Institute Milan, Italy

Doctor Eva Regina Haspinger is a Locum Consultant at the Medical Oncology Division of the National Cancer Institute of Milan, Italy. Dr. Haspinger received her medical degree in 2007 at the University of Innsbruck and achieved her board specialisation in Oncology in 2012 from the University of Verona. During her specialisation she attended at Temple University, Philadelphia (PA) and was involved in translational research. She is interested in different projects about thoracic malignancies, and is an active member of ESMO. Recent publications include: • Haspinger ER, Garassino MC, Torri V, Cinquini M, De Braud F, Gelsomino F. Do we really need another EGFR tyrosine Kinase Inhibitor in front line treatment for EGFR mutated NSCLC tumor patients? Correspondence, J Clin Oncol. 2014 Feb 3. • Pelosi G, Haspinger ER, Bimbatti M, Leone G, Paolini B, Fabbri A, Tamborini E, Perrone F, Testi MA, Garassino M, Maisonneuve P, de Braud F, Pilotti S, Pastorino U. Does immunohistochemestry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. Int J Surg Pathol. 2013 Dec 9. Dr. Haspinger has no conflict of interest to declare.

Doctor ROBERT A. HUDDART MD, PhD Reader & Honorary Consultant in Urological Oncology Institute of Cancer Research & Royal Marsden Hospital Sutton Surrey, United Kingdom

Doctor Robert A. Huddart is a Reader and Honorary Consultant at the Institute of Cancer Research (ICR) in the United Kingdom, and is an Honorary Consultant in Urological Oncology at the Royal Marsden Hospital (RMH) in London. Dr. Huddart completed his medical degree at Oxford University, then studied surgery at the University of London. He trained in Clinical Oncology at RMH and became a Fellow of the Royal College of Radiologists. He undertook a PhD in the Genetics of Testicular Cancer at ICR. In 1996, he was appointed as Senior Lecturer and Honorary Consultant in Clinical Oncology at ICR and RMH, and became Team leader in 2002. Dr. Huddart has worked as a Reader in Urological Oncology since 2007. He specialises in the management of urological cancer. His clinical interests cover all medical aspects of prostate, bladder, and testicular cancer, with a particular research interest in bladder and testicular cancer. He has led trials for ICR and RMH in both areas. His work particularly focuses on developing improvements in conservative treatment options in muscle-invasive bladder cancer. Dr. Huddart is the former chair and currently a member of the NCRI testis cancer study group, the NCRI bladder cancer study group and its chemotherapy subgroup and the CTRAD group. He is also Chief Investigator of the TE22 and TE23 studies and Co-investigator of the TRISST, 111 and Gem TIP studies. He is part of the trial development team of the TIGER trial, Chair of the South East England Testicular Cancer Network and a peer reviewer for the National Cancer Peer Review Team. In bladder cancer he was Chief Investigator for the SPARE trial of selective bladder preservation and the IDEAL study. He was also Co-Chief Investigator on the BC2001 trial and CoInvestigator for the BOXIT and ToTem trials. Recent publications include: • Huddart RA, Gabe R, Cafferty FH, et al. A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). Eur Urol. pii: S0302-2838(14)00608-3. doi: 10.1016/j.eururo.2014.06.034. [Epub ahead of print] • Huddart RA, Hall E, Hussain SA, et al. (2013) Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys.1;87(5):860. • Horwich, A., Dearnaely, D.P., Sohaib, A. et al. (2013) Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Annals of Oncology. 24: 2104–7. Dr. Huddart is a co-author on the following one study discussed: A randomised Phase 2 trial of intensive induction chemotherapy (CBOP/ BEP) and standard BEP in poor prognosis germ cell tumours.

Doctor VESA V. KATAJA MD, PhD Associate Professor of Clinical Oncology University of Eastern Finland Finland

Doctor Vesa V. Kataja is the Chief Medical Director for Central Finland Health Care District in Jyväskylä since March 2014. He is also Associate Professor of Clinical Oncology at the Department of Health Sciences, University of Eastern Finland, in Kuopio, Finland. Dr. Kataja studied in Wales, Canada, and Finland and received his physician’s license in 1985. He acquired the state qualification as Specialist in Medical Oncology and Radiotherapy in 1993. Following this, he was employed by the Sandoz Clinical Development Centre Ltd. in Frimley, United Kingdom, as a Medical Adviser in Oncology. From 1995 to 2006, he acted as the Deputy Head Physician at the Department of Oncology, KUH and as Consulting Clinical Oncologist in two hospitals. He then worked as Head of the Department of Oncology and Medical Director of the Conservative Clinics at Vaasa Central Hospital, Finland, until 2010. From Jan 2011 to Feb 2014, he acted as the Professor (fixed period) of Clinical Oncology at the University of Eastern Finland and the Head of the Cancer Center at Kuopio University hospital, Kuopio, Finland. Dr. Kataja’s basic research interest has been in the field of breast cancer genetics; however, his clinical research focuses on genitourinary tumours. He is a member of many professional societies, scientific boards and working groups internationally, including the European Society for Medical Oncology (ESMO). He is a active member of ESMO including the ESMO Publishing Working Group, and has previously served as a ESMO National Representative. He is also an ad hoc reviewer for several oncology journals. Recent publications include: • Fizazi K, Massard C, Bono P, Jones R, Kataja V et al. (2014). Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 2014. pii: S1470-2045(14)70240-2. doi: 10.1016/ S1470-2045(14)70240-2. [Epub ahead of print] • Milne RL, Burwinkel B, Michailidou K, et al. (2014). Common nonsynonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2014. pii: ddu311. [Epub ahead of print] • Li J, Lindström LS, Foo JN et al. (2014). 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nat Commun 2014 17;5:4051. doi: 10.1038/ncomms5051. Prof. Kataja has declared no potential conflicts of interest.

Doctor MAREN KNÖDLER MD University Cancer Center (UCCL) University of Leipzig, Leipzig, Germany

Doctor Maren Knödler is Chief Physician and head of the ambulance on site at UCCL, University of Leipzig, Leipzig, Germany. After receiving her medical degree in 2006, Dr. Knödler completed her residency training in internal medicine from 2006 to 2012 at Charité’s Division of Haematology and Oncology in Berlin. During this time, she was also an investigator for the coordinating centre for clinical trials at Charité (2006-2007). Dr. Knödler is currently an investigator for numerous national and international Phase II and III trials evaluating treatments for haematology and oncology disorders. She is the study coordinator and head of several national studies on specific antitumour therapies. Dr. Knödler is a member of various working groups and societies, including the working group for Head and Neck Cancer as well as working group for Young Medical Oncologists at the Association of Medical Oncology (AIO), which is connected to the German Cancer Society (Deutschen Krebsgesellschaft), and the German Society of Haematology and Oncology (DGHO). Recent publications include: • Pfisterer K, Fusi A, Klinghammer K, Knödler M, Nonnenmacher A, Keilholz U. Head Neck. 2014 Jan 13. PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. • Knoedler M, Gauler TC, Gruenwald V, Matzdorff A, Schroeder M, Dietz A, Jordan WO, Arnold D, Hennemann B, Hofele C, Weissinger F, Eberhardt W, Keilholz U. Oncology. 2013;84(5):284-9. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Dr. Knödler has declared no potential conflicts of interest.

Doctor KRISTIINA KOSKELA MD Oncologist Kuopio University Hospital Kuopio, Finland

Doctor Kristiina Koskela is an Oncologist within the radiotherapy unit of the Cancer Center at Kuopio University Hospital in Kuopio, Finland. Dr. Koskela received her state qualification in medicine and her physician’s licence in 2005 from Oulu University, Finland. Since 2009 she has worked in the field of oncology; she acquired the state qualification as Specialist in Clinical Oncology in 2013. She teaches oncology at Savonia University of Applied Sciences, and also works as a consultant at North Karelia Central Hospital, both in Finland. Dr. Koskela’s research interest lies in radiation oncology, specifically HDR and LDR brachytherapy. She is the principal investigator in the phase III clinical trial BRAVEROBO. Dr. Koskela has declared no potential conflicts of interest.

Doctor ALESSIA LEVAGGI MD Medical Doctor Division of Medical Oncology, Sant’ Andrea Hospital La Spezia, Italy

Dr. Alessia Levaggi is a Medical Doctor working in the Division of Medical Oncology at San Andrea Hospital in La Spezia, Italy. Dr. Levaggi was awarded her medical degree in 2007 from the University of Genoa, Italy, and began her specialisation in oncology at this university in the same year. From July 2011 she spent three years working at the IRCCS AOU San Martino-IST in Genova, Italy, after which Dr. Levaggi took up her present position in July 2014. Recent key publications include: • Lambertini M, Anserini P, Levaggi A, et al. Fertility counseling of young breast cancer patients. J Thorac Dis. 2013 Jun;5 Suppl 1:S68-80. • Levaggi A, De Maria A, Dozin B, et al. Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer. Anticancer Res. 2014 Jul 34(7):3715-20. • Levaggi A, Poggio F, Lambertini M. The burden of breast cancer from China to Italy. J Thorac Dis. 2014 Jun;6(6):591-4. Dr. Lavaggi has reported no conflicts of interest.

Doctor AMALIA MILANO MD Medical Doctor San Bartolomeo Hospital Sarzana, Italy

Doctor Amalia Milano is a Medical Doctor in the Division of Medical Oncology at San Bartolomeo Hospital in Sarzana, Italy. Dr. Milano received her medical degree in 2000 and her specialisation in Oncology in 2004, both from the University of Naples Federico II in Naples, Italy. She then worked at the Hospital of Prato in Prato, and completed fellowships at Fondazione G. Pascale and the University of Naples Federico II, Italy and the Jules Bordet Institute, Belgium. Recent key publications include: • Milano, A., Perri, F., Ciarmiello, A., et al. (2011) Targeted-therapy and imaging response: a new paradigm for clinical evaluation? Reviews on Recent Clinical Trials. 6: 259–65. • Apice, G., Milano, A., Bruni, G.S., et al. (2006) Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives. Reviews on Recent Clinical Trials. 1: 35–42. Dr. Milano has reported no potential conflicts of interest.

Doctor SARA PUSCEDDU MD Oncologist, Medical Oncology Division National Cancer Institute Milan, Italy

Doctor Pusceddu is a Medical Oncologist within the Medical Oncology Division, at the National Cancer Institute in Milan, Italy. She graduated in Medicine and Surgery at Cagliari University (110/110 cum laude), and her post-graduate education continued with a Medical Oncology Specialisation at Milan University (70/70 cum laude). Since 2004 she has been working at the Istituto Nazionale per lo Studio e la Cura dei Tumori in Milan, and is currently dedicated to the research and treatment of Neuroendocrine Tumours. She is a Member of the ENETS GEP-NET Center of Excellence at Istituto Nazionale Tumori Milano in Milan, and she participates actively as an Expert in Medical Oncology Tumour-board of GEP-NET Center. She is a member of leading national and international associations in Medical Oncology, including the Associazione Italiana di Oncologia Medica (AIOM) and the European Society for Medical Oncology (ESMO). She has actively participated as a co-investigator in numerous clinical trials in “Good Clinical Practice” carried out at the Istituto Nazionale Tumori Milano, and she is involved as a clinician as well as a co-investigator in research on Neuroendocrine and Gastrointestinal tumours. She has written and participated in the preparation of scientific publications on cancer issues. Recent publications include: • Bajetta, E., Catena, L., Fazio, N., Pusceddu, S., et al. (2014) Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study. Cancer. ;120(16):2457-63. • Verzoni E, Pusceddu S, Buzzoni R, et al. (2014) Safety profile and treatment response of everolimus in different solid tumors: an observational study. Future Oncol. ;10(9):1611-7. • Buzzoni R, Pusceddu S, Bajetta E, et al. (2014) Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Ann Oncol.;25(8):1597-603. Dr. Pusceddu has declared no potential conflicts of interest.

Doctor ROSA NADAL RIOS MD Johns Hopkins Hospital Johns Hopkins University Baltimore, USA

Doctor Rosa Nadal is a fellow at the Genitourinary Oncology Department at Johns Hopkins Hospital, Johns Hopkins University, Baltimore, USA. Dr. Nadal graduated in Medicine and Surgery in 2000 at the Universitat Autonoma de Barcelona, Barcelona, Spain. She completed her Medical Oncology Residency at the University Hospital de San Pau, in Barcelona, Spain. Upon completing her oncology training, she joined the faculty at the Solid Tumor Oncology Service of Hospital del Barcelona. In 2013, she was then appointed as a fellow to train in genitourinary malignancies at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. She is also currently completing her PhD thesis on the characterisation of circulating tumour cells from non-metastatic breast cancer patients. Her research interests focus on clinical genitourinary oncology and translational research that explores the prognostic/predictive significance of circulating tumour cells in cancer patients and tumor genetic analysis of patients with extreme outcomes from endocrine therapy. Recent publications include: • Nadal R, Ortega FG, Salido M et al. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer 2013. 133: 2398-2407. • Nadal R, Bellmunt J. New treatments for bladder cancer: when will we make progress? Curr Treat Options Oncol 2014. 15: 99-114. • Nadal R, Schweizer M, Kryvenko ON et al. Small cell carcinoma of the prostate. Nat Rev Urol. 2014; 11: 213-219. Dr. Rios has declared no potential conflicts of interest.

Doctor MARIANNA RONDINI MD Medical Doctor Division of Medical Oncology, Sant’ Andrea Hospital La Spezia, Italy

Doctor Marianna Rondini is a Medical Doctor in the Division of Medical Oncology at Sant’ Andrea Hospital in La Spezia, Italy. Dr. Rondini obtained her medical degree in 2000 from the University of Pisa, Italy, and focused her dissertation on breast cancer. In 2004, she gained a specialisation in Oncology by completing a phase II study in breast cancer, again at the University of Pisa. She then worked at Azienda USL 2 in Lucca, and completed fellowships at Sant’ Andrea Hospital, Ospedale Unico Versilia, Azienda USL 2 and the Medical School at the University of Pisa in Pisa, Italy. Recent publications include: • Camerini, A., Valsuani, C., Mazzoni, F., et al. (2010) Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advances non-small-cell lung cancer and poor performance status. Annals of Oncology. 21: 1290–5. • Camerini, A., Rondini, M., Garrone, O., et al. (2009) Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients. Cancer Biology and Therapy. 8: 1450–5. • Valsuani, C., Siclari, O., Camerini, A., et al. (2009) Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. Cases Journal. 2: 9133. Dr. Rondini has reported no potential conflicts of interest.

Doctor PATRICK ROTH MD Attending Physician University Hospital Zurich Zurich, Switzerland

Doctor Patrick Roth is an Attending Physician at the Department of Neurology and the coordinating physician of the Brain Tumour Center at the University Hospital Zurich, Switzerland. He specialises in the interdisciplinary management of brain tumour patients. He is involved in various clinical trials as well as being involved in preclinical research, to develop novel therapeutic strategies, with a focus on immunotherapeutic approaches for brain tumour patients. His current research focuses are the mechanisms underlying glioma immune escape, novel approaches to enhance the immunogenicity of glioma cells, and the analysis of new compounds for anti-glioma therapy. Recent publications include: • Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M. Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain 2013;136:564-76. • Silginer M, Weller M, Ziegler U, Roth P. Integrin inhibition promotes atypical anoikis in glioma cells. Cell Death Dis 2014;23;5:e1012 • Roth P, Stupp R, Eisele G, Weller M. Treatment of Primary CNS Lymphoma. Curr Treat Options Neurol 2014;16:277. • Tonder M, Eisele G, Weiss T, Hofer S, Seystahl K, Valavanis A, Stupp R, Weller M, Roth P. Addition of lomustine for bevacizumabrefractory recurrent glioblastoma. Acta Oncol 2014; May 26. [Epub ahead of print] Dr. Roth has served on advisory boards for MSD, Roche and Molecular Partners.

Doctor MAUSAM SINGHERA MD Clinical Research Fellow Institute of Cancer Research and The Royal Marsden NHS Foundation Trust Surrey, UK

Doctor Mausam Singhera is a Clinical Research Fellow at the Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in Surrey, UK. She is working towards a Doctor of Medicine (Res) degree; her project evaluates survivorship issues in testicular cancer survivors. She completed her medical training at Jawaharlal Nehru Medical College in Aligarh, India, and then trained in Clinical Oncology in 2010 in the UK. Recent publications include: • Maclean, J., Fersht, N., Singhera, M., et al. (2013) Multi-disciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study. Radiation Oncology. 8: 156. • Singhera, M. and Huddart, R. (2013) Testicular cancer: Changing patterns of incidence in testicular germ cell tumours. Nature Reviews Urology. 10: 312–4. • Singhera M, Huddart R. (2013) Comment on ‘Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors’. Br J Cancer. ;109(9):2502-3. Dr. Singhera has declared no potential conflicts of interest.

Doctor KONSTANTINOS TRYFONIDIS MD Medical Oncologist EORTC HQ Brussels, Belgium

Doctor Konstantinos Tryfonidis is a clinical research physician at EORTC HQ, appointed on behalf of the Breast Cancer Group and Elderly Task Force. Dr. Tryfonidis studied for his basic medical education in 2001 at the University of Brno, Czech Republic. From 2002 to 2003, he served as a doctor in Corinth, Greece. In 2003, he was appointed the Responsible Clinician for clinical trials, in the field of Cardiology, within the Department of Cardiology at the General Hospital of Corinth, a position he held until 2005. In 2006, Dr. Tryfonidis began his residency in internal medicine in the General Hospital of NIMTS in Athens. He completed his residency in medical oncology at the University Hospital of Heraklion, Greece from 2009-2012. He is currently completing his PhD thesis on pharmacogenomics in non-small cell lung cancer in the Laboratory of Cancer Biology, University of Crete, Greece. Dr. Tryfonidis is involved in the design and conduct of many phase II and III clinical trials in breast cancer and geriatric oncology, including a registration trial. Recent publications include: • Tryfonidis K, Kafousi M, Perraki M et al, The detection of circulating CK-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer. Clinical Breast Cancer Clin Breast Cancer. 2014 Jun 2. (Epub ahead of print). • Tryfonidis K, Boukovinas I, Xenidis N et al, A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2- negative metastatic breast cancer. Breast. 2013 Dec;22(6):1171-7. • Karachaliou, N., Ziras, N., Syrigos, K., et al. (2012) A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline – and taxane – pretreated patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 70: 169–76. Dr. Tryfonidis has declared no potential conflicts of interest.

Doctor ALISON YOUNG MD, MRCP Consultant Medical Oncologist St James’s University Hospital Leeds, United Kingdom

Doctor Alison C. Young is a Consultant Medical Oncologist within the Women’s Gynaecological team at St. James’s Institute of Oncology in Leeds and at the Leeds Cancer Centre, UK. Dr. Young trained in Medical Oncology in Leeds; she has been working as an NHS Medical Oncology Consultant since January 2012. Her clinical interests are in gynaecological cancers and acute oncology. She is the lead for Acute Oncology in Leeds and has developed the Acute oncology service for the Leeds Teaching Hospitals. Recent publications include: • Young, A.C., Craven, R.A., Cohen, D., et al. (2009) Analysis of VHL Gene Alterations and their Relationships to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clinical Cancer Research. 15: 7582-7592. • McCormick, R.I., Blick, C., Ragoussis, J., et al. (2012) miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. British Journal of Cancer. 108: 1133–42. • Young, A., Madi, A., Treanor, D., et al. (2010) Fulminant hepatic failure in a patient with advanced extragonadal germ cell tumour. BMJ Case Reports. pii: bcr0120102661. • E, Marshall., A, Young., & P, Selby. Editors (2014) Problem Solving in Oncology. Clinical Publishing 2014. Dr. Young has declared no potential conflicts of interest.

Doctor ZBIGNIEW (BEN) ZYLICZ MD, PhD Consultant in Palliative Medicine Palliative Centre Hildegard and University Hospital, Basel, Switzerland

Doctor Zbigniew (Ben) Zylicz is Head of the Research and Education Department of Palliative Centre Hildegard, and Consultant in Palliative Medicine in University Hospital in Basel, Switzerland. Dr. Zylicz completed his medicine degree in 1979, in Poland. From 1980 he trained in Internal Medicine and Medical Oncology at the universities of Nijmegen and Groningen in the Netherlands. In 1988 he successfully defended his thesis and was granted the title of Doctor at the University of Nijmegen. Having worked as a clinician in a regional hospital, Dr. Zylicz accepted the position of Medical Director at the Hospice Rozenheuvel in Rozendaal – one of the first Dutch hospices. Here he helped to develop palliative care in the Netherlands, for which he was decorated by HM Queen Beatrix with the Officers’ Cross of Orange Nassau. From 2005 to 2010, he formally specialised in Palliative Medicine as the medical director of a large hospice in Hull in the United Kingdom. Dr. Zylicz specialises in pain, itch, and pruritus in cancer, as well as opioid pharmacology, opioid induced hyperalgesia, and end-of-life medical ethics. He has edited several academic textbooks and authored hundreds of articles in peer-reviewed journals. Recent publications include: • Hanna, M. and Zylicz, Z. (2013) Cancer Pain. London: Springer. • Zylicz, Z. (2004) Pruritus in advanced disease. Oxford: Oxford University Press. Dr. Zylicz has reported he is a member of OPENMINDS. An advisory board member of Mandipharma International. He has received honoraria for lecturing from Grünenthal and Mundipharma.

Professor CARLO ASCHELE MD, PhD Head of Medical Oncology and Hematology Felettino Hospital La Spezia, Italy

Professor Carlo Aschele is Head of the Medical Oncology and Haematology Unit at the Ospedale del Felettino, Italy. He also has a post as Professor of Medical Oncology in the School of Specialization in Medical Oncology at the University of Genoa, Italy. Prof. Aschele received his medical degree from the University of Genoa, Italy. He then specialised in Medical Oncology and served as Research Fellow at the Memorial Sloan-Kettering Cancer Center, USA. Receiving a PhD in Oncology from the University of Bologna, Italy, Prof. Aschele worked as a Consultant Medical Oncologist and as Assistant Medical Director at the National Institute for Cancer Research in Genoa, Italy. His research has focused on the treatment of gastrointestinal cancer, including the development and clinical assessment of new drugs and regimens. Prof. Aschele is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the Italian Association of Medical Oncology. He helped to set up and still chairs the STAR-Network, an Italian network of hospital and university centres conducting multidisciplinary clinical trials in gastrointestinal cancer. Prof. Aschele has authored over 50 peer-reviewed scientific publications within indexed medical journals. He has served on the editorial board of Oncology Reports and serves as a reviewer for the British Journal of Cancer, Critical Reviews in Oncology/Hematology, Annals of Oncology, and the Journal of Clinical Oncology. Recent publications include: • Aschele, C., Coinini, L., Lonardi. S., et al. (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. Journal of Clinical Oncology. 29: 2773-80. • Aschele, C. and Lonardi, S. (2007) Addition of weekly oxalipatin to standard preoperative chemoradiation for locally advanced rectal cancer. Jounral of Clinical Oncology. 25: 602-3. • Aschele, C., Friso, M.L., Pucciarelli, S., et al. (2005) A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Annals of Oncology. 16: 1140-6. Prof. Aschele has reported no potential conflicts of interest.

Professor ANDREAS DIETZ Chairman Clinic of Otolaryngology University of Leipzig Leipzig, Germany

Professor Andreas Dietz is the Director of the ENT Department at the University Hospital of Leipzig, Germany. Prof. Dietz undertook his early medical education in Budapest, Hungary, and in Giessen and Heidelberg, Germany, receiving his medical degree from the University of Heidelberg, Germany. He is a fully trained head, neck, ear, nose, and throat surgeon. He began work as an Assistant Doctor and was then appointed as an otolaryngology specialist, before being employed as a Consultant at the Department of Otolaryngology at the University of Heidelberg, Germany. From 2000 to 2004, Prof. Dietz worked as an Assistant Professor at the Department of Otolaryngology; in 2004 he was appointed as Chairman and Professor of the ENT Department at the University of Leipzig. He specialises in head and neck oncology, ear surgery, nose and sinus surgery (FESS), laryngeal framework surgery, salivary gland surgery and surgery of the facial nerve. He has been conducting clinical trials since 1993, and is involved in teaching and developing new Harvard-based teaching strategies at the universities of Heidelberg and Leipzig. Prof. Dietz is a member of several academic and scientific societies. He serves as a board member of the Innovation Centre of Computer Assisted Surgery and the German National Head and Neck Oncology Group. He is a board member of the German Larynx Preservation Group (Deutschen Organerhaltstudiengruppe), and serves as a scientific council member for the European Laryngeal Society. Prof. Dietz is also a Member of Honor of the Royal Belgian ENT Society and the Indian Head and Neck Foundation. He is director of the IRDCAcademy Leipzig and is an editor of the scientific German journal Laryngo-Rhino-Otologie (Thieme Germany). Recent publications include: • Gerlach MM., Merz F., Wichmann G., Kubick C., Wittekind C., Lordick F., Dietz A., Bechmann I. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer. 2014 Jan 21;110(2):479-88. • Mozet C., Stoehr M., Dimitrova K., Dietz A., Wichmann G. Hedgehog targeting by cyclopamine suppresses head and neck squamous cell carcinoma and enhances chemotherapeutic effects. Anticancer Res. 2013 Jun;33(6):2415-24. • Singer S., Danker H., Guntinas-Lichius O., Oeken J., Pabst F., Schock J., Vogel HJ., Meister EF., Wulke C., Dietz A. Quality of life before and after total laryngectomy: Results of a multicenter prospective cohort study. Head Neck. 2013 Jun 1. doi: 10.1002/ hed.23305. [Epub ahead of print] Prof. Dietz is a paid consultant for Merck Serono.

Professor MARTIN DREYLING MD Professor of Medicine University Hospital Großhadern Munich, Germany

Professor Martin Dreyling is Professor of Medicine and Head of the Lymphoma Program at the Department of Medicine III, University Hospital Großhadern, Germany. Prof. Dreyling studied at the universities of Düsseldorf, Giessen, Tübingen and Würzburg in Germany. He completed his clinical training at the universities of Bonn, Münster, Göttingen and Munich in Germany. He worked as a Visiting Scientist at the University of Chicago, USA, from 1992 to 1995. He now focuses on the molecular basis of malignant transformation, as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including novel antibodies and molecular targeted approaches like inhibitors of the B-cell receptor pathway. Prof. Dreyling is a member of various societies and organisations including the American Society of Clinical Oncology, American Society of Hematology, the Germany Association for Hematology and Oncology, the European Hematology Association, and the European Society for Medical Oncology (ESMO). He is Coordinator of the European MCL Network and Assistant Coordinator of the German Low Grade Lymphoma Study Group. He has co-authored numerous scientific papers, book chapters, and abstracts in international peerreviewed journals. Recent publications include: • Kluin-Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug; 367: 520-531 • Ghielmini M, Vitolo U, Kimby E et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24: 561-576 • Dreyling M, Thieblemont C, Gallamini A et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013; 24: 857-877 Prof. Dreyling has reported scientific advisory boards for Bayer, Celgene, Gilead, Janssen, Pfizer; speaker’s honoraria for Celgene, Janssen, Pfizer, Roche; support of academic events for Celgene, Janssen, Mundipharma, Pfizer, Roche.

Professor JOHN HAANEN MD, PhD Head, Division of Medical Oncology The Netherlands Cancer Institute Amsterdam, the Netherlands

Professor John B. Haanen is Head of the Division of Medical Oncology and Staff Scientist in the Division of Immunology at the Netherlands Cancer Institute, Amsterdam, the Netherlands. He is also Professor of Translational Immunotherapy of Cancer at Leiden University Medical Centre, the Netherlands. Prof. Haanen received his medical degree from the University of Leiden, then completed a PhD on human CD4+ helper T cells at the Department of Immunohematology and the Blood Bank of the Leiden University Medical Centre and the DNAX Research Institute in California, USA. He then trained in internal medicine at Leiden University Medical Centre and at Bronovo Hospital in The Hague, the Netherlands. He also trained in intensive care medicine at Leiden University Medical Centre, and in immunology and medical oncology at the Netherlands Cancer Institute. His research focuses on the translation of novel immunotherapy and targeted therapy strategies into clinical practice. His clinical medical oncology practice is focused on melanoma and renal cell carcinoma patients. He holds the UICC/Dutch Cancer Society International Cancer Technology Transfer Fellowship. Prof. Haanen is a Co-founder of the Amsterdam Biotherapeutics Unit and Chairman of The Dutch Tumor Immunology Working Party for renal cell carcinoma. He serves on various advisory boards and committees, including the editorial board of Current Oncology Reports. Recent publications include: • Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB et al. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer. 2014 May; 110: 2441-2449. • Powles T, Kayani I, Sharpe K, Lim L, Peters J, Stewart GD, Berney D, Sahdev A, Chowdhury S, Boleti E, Shamash J, Reynolds AR, Jones R, Blank C, Haanen J, Bex A. A prospective evaluation of VEGFtargeted treatment cessation in metastatic clear cell renal cancer. Ann Oncol. 2013 Aug;24: 2098-2103. • McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, et al. A. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 Mar; 15:323-332. • van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D, Nieuwland M, Stratton MR, Kerkhoven RM, Kesmir C, Haanen JB, Kvistborg P, Schumacher TN. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013 Nov 10;31:439-442. Prof. Haanen has declared a consultancy role for Pfizer.

Professor GUNTER VON MINCKWITZ MD, PhD Managing Director German Breast Group Neu-Isenburg, Germany

Professor Gunter von Minckwitz is the Managing Director of the breast cancer research facility German Breast Group Research Institute. He is the Alternate Director at Senologic Oncology in Düsseldorf, Germany, and a Professor at the University of Frankfurt. Prof. von Minckwitz studied medicine from 1983 to 1990 at the University of Heidelberg, Germany, and received his doctorate there in 1991. He worked as a Medical Assistant first at the local Women’s Hospital. From 1998 to 2008, he served as Chief Physician and from 2003 to 2009, he worked as an Assistant Medical Oncologist. His research interests include systemic treatment of all stages of breast cancer. He has led a large number of national and international clinical trials and has improved the infrastructure for breast cancer trials throughout Germany. In addition, he founded (and previously led) the development of the National Treatment Guidelines for Breast Cancer, that are published by the German working group AGO. Prof. von Minckwitz was a member of the board of the directors of the Breast International Group until 2014. He is a member of the St. Gallen consensus panel and serves on the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). He is on the editorial board for Breast Care, and acts as a scientific advisor for Senology and Gyn Spectrum. Recent publications include: • von Minckwitz G, Blohmer JU, Costa SD et al. J Clin Oncol. Response-guided neoadjuvant chemotherapy for breast cancer. 2013; 31: 3623-3630. • Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 . pii: S0140-6736(13)62422-8. doi: 10.1016/S0140-6736(13)62422-8. [Epub ahead of print] • von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014. pii: S1470-2045(14)70160-3. doi: 10.1016/ S1470-2045(14)70160-3. [Epub ahead of print] Prof. von Minckwitz has reported receiving research funds from Sanofi-Aventis, Glaxo SK and Roche. He has also received consultancy and/or honoraria from Roche.

Professor TIMOTHY J. PERREN MD, FRCP Professor of Women’s Cancers and Oncology, Honorary Consultant Medical Oncologist Leeds Institute of Cancer, Medicine and Pathology Leeds, United Kingdom

Professor Timothy J. Perren is a Consultant Medical Oncologist at the St James’s Institute of Oncology in the United Kingdom. Prof. Perren trained in Medical Oncology first in Birmingham and subsequently at the Royal Marsden Hospital in London. He was a Senior Lecturer in Medical Oncology at the University of Leeds and St James’s University Hospital prior to becoming an NHS Consultant Medical Oncologist in April 2000. He was appointed to the chair of Women’s Cancers and Oncology at the University of Leeds in October 2013. His clinical interests span breast and gynaecological cancers, and he has a long-standing interest in clinical trials that explore the development of new and better treatments for these cancers. Prof. Perren has been a member of the UK National Cancer Research Institute’s Gynaecological Cancer clinical Studies Group since its inception; he also serves on the clinical trial steering committees for a number of the current and recent national phase III trials in breast and gynaecological cancers. Recent publications include: • Kehoe, S., Hook, S., Nankivell, M., et al. (2013) Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial. Journal of Clinical Oncology. 31: No 15_suppl 5500. • Collinson, F.J., Seligmann, J., and Perren, T.J. (2012) Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents. Current Oncology Reports. 14: 509–18. • Perren TJ, Swart AM, Pfisterer J, et al. (2011) A Phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. Prof. Perren as Chief Investigator of ICON7 has received research funding from Roche. He has also attended remunerated advisory boards for Roche concerning bevacizumab in ovarian cancer. He has received honoraria for speaking at Roche sponsored meetings and has received funding to attend meetings and conferences. Dr. Perren has also received honoraria and travel expenses from Novartis in respect of his role as UK Chief Investigator in the Bolero-3 trial.

Professor GHAZALEH TABATABAI MD, PhD Professor of Neuro Oncology Eberhand Karls University of Tübingen Tübingen, Germany

Professor Ghazaleh Tabatabai is a professor of NeuroOncology at the Eberhard Karls University of Tübingen and affiliated with the Departments of Neurosurgery and Neurology at the University Hospital of Tübingen, Germany. She specialises in clinical and preclinical neuro-oncology and aims to improve the therapeutic options for brain tumour patients. Her current research goals are to design cell-based gene therapies against malignant gliomas and investigate molecular mechanisms of therapy resistance. Recent publications include: • Wirsching HG, Krishnan S, Florea AM, Frei K, Krayenbühl N, Hasenbach K, Reifenberger G, Weller M, Tabatabai G. Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain 2014;137:433-48. • Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M. Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain 2013;136:564-76. • Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 2013;81:1515-22. Prof. Tabatabai has served on advisory boards for MSD and Roche, and received travel grants from MSD.